Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Initial Data from the Ongoing Ph 2B VITALIZE Trial in Patients with r/r DLBCL announced

December 19, 2022

80% ORR reported in Final Cohort of Ph 1 Single Agent Trial of Annamycin for the Treatment of AML

December 19, 2022

Double-Digit ORR announced in Each Cohort from the Ongoing ENVASARC Ph 2 Pivotal Trial

December 19, 2022

Pluvicto™ shows statistically significant and clinically meaningful rPFS benefit in patients with PSMA–positive mCRPC

December 12, 2022

PERLA Ph 2 trial of Jemperli (dostarlimab) plus chemotherapy shows positive results in 1L mNSCLC

December 12, 2022

New Data from the OPTIMA II Study Shows mDOR of 24.4 Months for UGN-102 in patients with Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer

December 12, 2022

70% CR with NKX019 announced in patients with R/R NHL

December 12, 2022

Preliminary Results from Trial of Berubicin for the Treatment of Recurrent GBM announced

December 12, 2022

FAILED TRIAL: Ph 3 CONTACT-01 trial of cabozantinib + atezolizumab in IO- and chemo-treated mNSCLC patients did not meet its primary endpoint of OS

December 12, 2022

Jemperli (Dostarlimab-Gxly) RUBY Ph 3 Trial Met Its Primary Endpoint In A Planned Interim Analysis In Patients With Primary Advanced Or Recurrent Endometrial Cancer

December 5, 2022

New Data from the OLYMPUS Trial Shows mDOR of 28.9 Months for JELMYTO for Adults with Low-Grade Upper Tract Urothelial Cancer

December 5, 2022

ARV-471 Achieves a CBR of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Ph 2 Expansion Trial (VERITAC)

November 30, 2022

Ph 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

November 30, 2022

Positive Top-Line Results From Ph 3 Trial of DCVax®-L for Glioblastoma announced

November 23, 2022

Ph 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL

November 23, 2022

INT230-6 +/- Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising OS Results in Adult Subjects with Metastatic Sarcomas

November 23, 2022

Topline Data from the Ph 2 MIRAGE Study of Zandelisib in Patients with Indolent B-cell NHL in Japan announced

November 23, 2022

Positive Topline Result in Fruquintinib Ph 3 FRUTIGA Study in 2L Gastric Cancer in China announced

November 23, 2022

MARIO-3 Updates reported in Patients with 1L mTNBC Suggesting Potential Long-Term Patient Benefit of Eganelisib

November 23, 2022

100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Ph 2 Trial announced

November 23, 2022

New Ph 2 Data with CG0070 + KEYTRUDA in BCG-Unresponsive NMIBC patients announced

November 23, 2022

Durable Responses of Botensilimab/Balstilimab Combination in Nine Different Treatment-Resistant Cancers announced

November 23, 2022

New Positive Data from Ongoing Ph 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer presented

November 16, 2022

Additional efficacy analysis in Phase 2 study of VB10.16 in combination with atezolizumab in advanced cervical cancer announced

November 16, 2022

Updated Overall Survival Results from GRANITE Ph 1/2 Study announced

November 16, 2022
Page1 … Page25 Page26 Page27 Page28 Page29 Page30

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.